Trial results

$VIR — elebsiran and tobevibart

Vir Biotechnology, Inc. (VIR) elebsiran and tobevibart: trial results in Chronic hepatitis delta, 2026.

Research by Catalyst Intel

The catalyst

"Topline data from the pivotal ECLIPSE 1 trial are expected in the fourth quarter of 2026."

— Vir Biotechnology, 8-K filed 2026-11-04 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

VIR-ELEBSIRANAND-2026

Company

Vir Biotechnology, Inc.

Kind

Trial results

Indication

Chronic hepatitis delta

Window

2026-01-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.